Drug intelligence / Profile preview

ado-trastuzumab emtansine + ribociclib

Development stage: Unknown
Lead developer: Genentech
Modality: Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous, Oral

Overview

A combination therapy consisting of ado-trastuzumab emtansine (T-DM1), an antibody-drug conjugate targeting HER2-positive cancer cells, and ribociclib, a CDK4/6 inhibitor. This combination is being investigated for the treatment of HER2-positive metastatic breast cancer in patients previously treated with trastuzumab and taxanes. Preclinical evidence suggests synergy between CDK4/6 inhibitors and anti-HER2 therapies.

Brand names: Kadcyla + Kisqali
Other names: ribociclib + T-DM1

Targets

MicrotubuleCDK4 (Cyclin-dependent kinase 4)CDK6 (Cyclin-dependent kinase 6)ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on ado-trastuzumab emtansine + ribociclib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ado-trastuzumab emtansine + ribociclib.

Explore the full profile